BA
WX

BlackRock Advisors’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

BlackRock Advisors’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-54,937
Closed -$2.37M – 3873
2015
Q3 		$2.37M Buy
54,937
+632
+1% +$26.7K ﹤0.01% 1307
2015
Q2 		$2.29M Buy
54,305
+2,486
+5% +$105K ﹤0.01% 1208
2015
Q1 		$2.01M Sell
51,819
-19,441
-27% -$749K ﹤0.01% 1224
2014
Q4 		$2.4M Sell
71,260
-4,662
-6% -$165K ﹤0.01% 1143
2014
Q3 		$2.66M Buy
75,922
+226
+0.3% +$7.75K ﹤0.01% 1102
2014
Q2 		$2.49M Sell
75,696
-61,926
-45% -$2.12M ﹤0.01% 1121
2014
Q1 		$5.07M Sell
137,622
-43,103
-24% -$1.58M 0.01% 967
2013
Q4 		$6.94M Sell
180,725
-88,622
-33% -$2.8M 0.01% 913
2013
Q3 		$7.38M Sell
269,347
-37,616
-12% -$891K 0.01% 872
2013
Q2 		$6.45M Buy
+306,963
New +$5.99M 0.01% 891

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

BlackRock Advisors's WX Position: Q4 2015 in Review

BlackRock Advisors sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 54,937 shares — an estimated $2.37M sold.

BlackRock Advisors first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $7.38M in Q3 2013. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • BlackRock Advisors reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • BlackRock Advisors sold 54,937 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $2.37M.
  • BlackRock Advisors first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • BlackRock Advisors's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $7.38M in Q3 2013.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on BlackRock Advisors's 13F filing for Q4 2015, filed 11 Feb 2016.